Treatment of advanced radioactive iodine refractory follicular thyroid cancer with multy kinase inhibitor Lenvatinib: a сase report

Only a few patients with differentiated thyroid cancer (less than 10% of patients with clinical disease) develop distant metastases. Two third of these patients become refractory to the treatment with radioactive iodine (RAI). After the discovery of advanced RAI-refractory disease, the 10-year survival rate is usually less than 10% and the mean life expectancy is 3-5 years. Systemic chemotherapy has a limited efficacy with a high toxicity rate. Multikinase inhibitors are being studied the most extensively in relation to advanced RAI-refractory disease. Two of multikinase inhibitors, lenvatinib and sorafenib have shown an objective response rate and have significantly improved the progression-free survival rates.